Trade CLLS stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Cellectis S.A. American Depositary Shares (CLLS) is trading at US$1.04, down 5.88% today as of Oct 16, 16:00 EDT. The company has a market capitalisation of US$342.89M. Over the past 52 weeks, CLLS has traded between US$1.03 and US$5.45. On Syfe you can trade CLLS with $0 commission and add it to your watchlist.
| Previous close | US$1.11 |
|---|---|
| Market cap | US$342.89M |
| 52-week range | US$1.03 – US$5.45 |
| Volume | 81.36K |
| Exchange | US |
Cellectis S.A. American Depositary Shares
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Year: 2015
Barclays Downgrades Cellectis to Underweight From Overweight, Adjusts PT to $1.30 From $9
Sep 16, 10:37 AM · MT Newswires
Top Midday Decliners
Sep 14, 7:01 PM · MT Newswires
Cellectis Shares Fall After Realigning Focus to Become in Vivo Gene Editing Company
Sep 14, 6:55 PM · MT Newswires
Cellectis Says Phase 1 Lasme-cel Study Shows 100% Response Rate in B-Cell Leukemia Patients
Jun 11, 3:57 PM · MT Newswires
Cellectis Says US FDA Granted RMAT Designation to Lasme-cel to Treat r/r B-ALL Patients
Jun 9, 8:58 PM · MT Newswires
Stay on top of CLLS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
